First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

Phase I, Open-Label, Multicenter, Dose-Escalation Study Of The Tyrosine Kinase Inhibitor Of VEGFR-2, AG013736, In Patients With Advanced Solid Tumors

The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.

Inclusion Criteria:

• Patients with cytologically or histologically confirmed solid tumor(s) and with at least one measurable disease site
• Patients with adequate bone marrow, liver and kidney function
• Patients with life expectancy of at least 12 weeks

Exclusion Criteria:

• Patients who have received chemotherapy, immunotherapy, radiotherapy or any investigational agent within 4 weeks of study entry
• Patients with have had a major surgical procedure within 4 weeks of study entry